focus -WSS

focus

author：comprehensive 2025-09-28 01:37:48 - browse：153

Stoke Therapeutics is still seeking an effective dose for an experimental drug to treat a severe form of childhood epilepsy, following the release of updated data Tuesday that showed disappointing reductions in convulsive seizure activity.

In the latest look at an ongoing mid-stage study, three monthly injections of the Stoke drug, called STK-001, given at a 45-mg dose, resulted in a median 18% reduction in convulsive seizure activity, compared to baseline.

The new analysis was conducted on 16 children diagnosed with a rare form of epilepsy called Dravet syndrome. Last November, in six patients, the drug showed a median 55% reduction in seizure activity.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Hospital price transparency does save money, advocate argues

WSS

STAT Readout Newsletter: Today's biggest biotech updates

The EU Joint Clinical Assessment needs to live up to its promise

STAT Summit: GSK CEO on pharma giant's new direction

Solve the antibiotic resistance crisis with preventive drugs

HHS leader on health, climate change and biopharma emissions

Researchers explore possible ties between long Covid, menopause

Wikipedia

focus

focus

Jerome Adams on the need for new antivirals for Covid

Studies point to risks of excluding people with obesity from drug trials

Bright Health sells Medicare Advantage business to Molina

Studies point to risks of excluding people with obesity from drug trials

Peter Hotez and the public health issue of online harassment

STAT Readout Newsletter: Today's biggest biotech updates

Medicare proposal to cover medical devices draws a mixed reaction

STAT Summit: GSK CEO on pharma giant's new direction

New air purifier tech could be key to improving indoor air quality

RSV shot was 90% effective at preventing hospitalizations in kids

hotspot

FDA warns J&J's Abiomed: We will regulate your software

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

Pharmacists can make shortage drugs, but at what cost?

Change Healthcare cyberattack prompts Medicare loan program

The EU Joint Clinical Assessment needs to live up to its promise

Studies point to risks of excluding people with obesity from drug trials

knowledge

leisure time

explore

Wikipedia